🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

82 results for “Chen” Clear

  1. Ezutromid

    Summit Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  2. HT-100

    Processa Pharmaceuticals

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    2 trials

  3. ITF2357

    Italfarmaco S.p.A.

    Duchenne muscular dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  4. Ifetroban

    CUMBERLAND PHARMACEUTICALS INC

    Duchenne Muscular Dystrophy Cardiomyopathy

    phase 2 small molecule completed

    1 trial

  5. LP-10 (Liposomal Tacrolimus)

    LIPELLA PHARMACEUTICALS INC.

    Oral Lichen Planus

    phase 2 small molecule active

    1 trial

  6. PBGENE-DMD (IV)

    Chongqing Precision Biotech Co., Ltd

    Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

    phase 2 mab active

    1 trial

  7. PRO044 SC

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  8. PRO044 SC 6 mg/kg

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  9. PRO045, 0.15 mg/kg/week

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  10. PTC124

    PTC THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  11. Placebo

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  12. Regimen Selection Phase Group 2

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  13. SGT-001

    Solid Biosciences

    Duchenne Muscular Dystrophy

    phase 2 gene therapy active

    1 trial

  14. SODIUM CHLORIDE, ENTR-601-45

    Entrada Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  15. SRP-5051

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 2 small molecule terminated

    2 trials

  16. Sevasemten Dose 1

    Edgewise Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    2 trials

  17. TAS-205

    Taiho Pharma Netherlands B.V.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  18. The placebo is commercially available 5% dextrose solution intended for IV, DYNE-251, DYNE-251

    Dyne Therapeutics

    Duchenne muscular dystrophy

    phase 2 small molecule active

    1 trial

  19. VESLETEPLIRSEN(SRP-5051)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  20. Vesleteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  21. delandistrogene moxeparvovec

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 2 gene therapy active

    2 trials

  22. A study to learn how vamorolone affects the body, how safe it is and how it moves into, through and out of the body in healthy male participants

    Lacuna Pharma Pty Ltd

    Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy

    phase 1 other active

    1 trial

  23. CRD-TMH-001

    Ultragenyx UK Limited

    Duchenne Muscular Dystrophy

    phase 1 small molecule active

    1 trial

  24. Evaluation of vamorolone CYP3A4 induction on midazolam (a sensitive CYP3A4 substrate) pharmacokinetics

    Lacuna Pharma Pty Ltd

    Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources